CoChat
Sign Up
Cited by 218Nanoplatforms for cancer theranosticsNanoparticle-Based Drug DeliveryNanotechnology research and applications

Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy

Open access
Jo, Sung Duk, Ku, Sook Hee, Won, You-Yeon, Kim, Sun Hwa, Kwon, Ick Chan·2016·Theranostics
DOI 10.7150/thno.15335PMC PMC4924505
Open this paper in CoChat — free accountOpen PDF

Abstract

Recently, many theranostic nanomaterials have been developed by integrating therapeutic and diagnostic agents in a single regimen. Real-time visualization of nano drug carrier biodistributions, drug release processes and therapeutic responses can provide critical information needed for dynamically optimizing treatment operations in a personalized manner in real time. This review highlights recent progresses in the development of multifunctional nanoparticles possessing both therapeutic and imaging functionalities for cancer therapy. The advantages of using nanoparticle platforms are discussed. Examples demonstrating various combinations of imaging and therapeutic modalities are highlighted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.15335

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Theranostics has been most successfully implemented in oncology.

    “To date, theranostics has been most successfully implemented in oncology [32].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [32]

    The Introduction and Conclusions discuss theranostic approaches to cancer treatment, supporting oncology as an application. They do not compare oncology with other fields or establish that it has been the most successful; the Conclusions also note that most theranostic nanoparticle systems have not yet been studied for safety in humans. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • The key success factor for theranostics in oncology is the presence of solid tumors with disrupted vascular architecture, which provides a pronounced EPR effect.

    “The key success factor is the presence of solid tumors with disrupted vascular architecture, which provides a pronounced enhanced permeability and retention (EPR) effect [32,34].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [32]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 77

  1. [1]Lammers T Aime S Hennink WE Storm G Kiessling F Theranostic nanomedicine Acc Chem Res 2011 44 1029 38 21545096
  2. [2]Rizzo LY Theek B Storm G Kiessling F Lammers T Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications Curr Opin Biotechnol 2013 24 1159 66 23578464 PMC3833836
  3. [3]Burrell RA McGranahan N Bartek J Swanton C The causes and consequences of genetic heterogeneity in cancer evolution Nature 2013 501 338 45 24048066
  4. [4]Lammers T Rizzo LY Storm G Kiessling F Personalized nanomedicine Clin Cancer Res 2012 18 4889 94 22829203
  5. [5]Choi KY Liu G Lee S Chen X Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives Nanoscale 2012 4 330 42 22134683 PMC3629960
  6. [6]Xie J Lee S Chen X Nanoparticle-based theranostic agents Adv Drug Deliv Rev 2010 62 1064 79 20691229 PMC2988080
  7. [7]Kobayashi H Watanabe R Choyke PL Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2013 4 81 9 24396516 PMC3881228
  8. [8]Peer D Karp JM Hong S FaroKHzad OC Margalit R Langer R Nanocarriers as an emerging platform for cancer therapy Nat Nanotechnol 2007 2 751 60 18654426
  9. [9]Petros RA DeSimone JM Strategies in the design of nanoparticles for therapeutic applications Nat Rev Drug Discov 2010 9 615 27 20616808
  10. [10]Albanese A Tang PS Chan WC The effect of nanoparticle size, shape, and surface chemistry on biological systems Annu Rev Biomed Eng 2012 14 1 16 22524388
  11. [11]Papahadjopoulos D Allen TM Gabizon A Mayhew E Matthay K Huang SK Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci U S A 1991 88 11460 4 1763060 PMC53155
  12. [12]Hatakeyama H Akita H Harashima H The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors Biol Pharm Bull 2013 36 892 9 23727912
  13. [13]Perrault SD Walkey C Jennings T Fischer HC Chan WCW Mediating Tumor Targeting Efficiency of Nanoparticles Through Design Nano Lett 2009 9 1909 15 19344179
  14. [14]Perry JL Reuter KG Kai MP Herlihy KP Jones SW Luft JC PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics Nano Lett 2012 12 5304 10 22920324 PMC4157665
  15. [15]Lee DE Koo H Sun IC Ryu JH Kim K Kwon IC Multifunctional nanoparticles for multimodal imaging and theragnosis Chem Soc Rev 2012 41 2656 72 22189429
  16. [16]Huang Y He S Cao W Cai K Liang XJ Biomedical nanomaterials for imaging-guided cancer therapy Nanoscale 2012 4 6135 49 22929990
  17. [17]Ryu JH Koo H Sun IC Yuk SH Choi K Kim K Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy Adv Drug Deliv Rev 2012 64 1447 58 22772034
  18. [19]Ding H Wu F Image guided biodistribution and pharmacokinetic studies of theranostics Theranostics 2012 2 1040 53 23227121 PMC3516836
  19. [20]He X Wang K Cheng Z In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 349 66 20564463
  20. [21]Na JH Koo H Lee S Min KH Park K Yoo H Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models Biomaterials 2011 32 5252 61 21513975
  21. [22]Na JH Lee SY Lee S Koo H Min KH Jeong SY Effect of the stability and deformability of self-assembled glycol chitosan nanoparticles on tumor-targeting efficiency J Control Release 2012 163 2 9 22846988
  22. [23]Nam HY Kwon SM Chung H Lee SY Kwon SH Jeon H Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles J Control Release 2009 135 259 67 19331853
  23. [24]Kim K Kim JH Park H Kim YS Park K Nam H Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring J Control Release 2010 146 219 27 20403397
  24. [25]Chung EJ Cheng Y Morshed R Nord K Han Y Wegscheid ML Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma Biomaterials 2014 35 1249 56 24211079 PMC3880134
  25. [26]Lai J Shah BP Garfunkel E Lee KB Versatile fluorescence resonance energy transfer-based mesoporous silica nanoparticles for real-time monitoring of drug release ACS nano 2013 7 2741 50 23445171 PMC3626425
  26. [27]Wu X Sun X Guo Z Tang J Shen Y James TD In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug J Am Chem Soc 2014 136 3579 88 24524232
  27. [28]Schellenberger EA Bogdanov A Petrovsky A Ntziachristos V Weissleder R Josephson L Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy Neoplasia 2003 5 187 92 12869301 PMC1502408
  28. [29]Brindle K New approaches for imaging tumour responses to treatment Nat Rev Cancer 2008 8 94 107 18202697
  29. [30]Riedl SJ Shi Y Molecular mechanisms of caspase regulation during apoptosis Nat Rev Mol Cell Biol 2004 5 897 907 15520809
  30. [31]Zhang R Lu W Wen X Huang M Zhou M Liang D Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis J Nucl Med 2011 52 958 64 21571801 PMC3463236
  31. [32]Zhang R Huang M Zhou M Wen X Huang Q Li C Annexin A5-functionalized nanoparticle for multimodal imaging of cell death Mol Imaging 2013 12 182 90 23490444 PMC3893065
  32. [33]Lee S Choi KY Chung H Ryu JH Lee A Koo H Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe Bioconjug Chem 2011 22 125 31 21218786
  33. [34]Choi KY Jeon EJ Yoon HY Lee BS Na JH Min KH Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer Biomaterials 2012 33 6186 93 22687759 PMC3617484
  34. [35]Dolmans DE Fukumura D Jain RK Photodynamic therapy for cancer Nat Rev Cancer 2003 3 380 7 12724736
  35. [36]Lee SJ Koo H Jeong H Huh MS Choi Y Jeong SY Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy J Control Release 2011 152 21 9 21457740
  36. [37]Yoon HY Koo H Choi KY Lee SJ Kim K Kwon IC Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy Biomaterials 2012 33 3980 9 22364699
  37. [38]Shen J Zhao L Han G Lanthanide-doped upconverting luminescent nanoparticle platforms for optical imaging-guided drug delivery and therapy Adv Drug Deliv Rev 2013 65 744 55 22626980
  38. [39]Yang D Ma P Hou Z Cheng Z Li C Lin J Current advances in lanthanide ion (Ln(3+))-based upconversion nanomaterials for drug delivery Chem Soc Rev 2015 44 1416 48 24988288
  39. [40]Park YI Lee KT Suh YD Hyeon T Upconverting nanoparticles: a versatile platform for wide-field two-photon microscopy and multi-modal in vivo imaging Chem Soc Rev 2015 44 1302 17 25042637
  40. [41]Ma P Xiao H Li X Li C Dai Y Cheng Z Rational design of multifunctional upconversion nanocrystals/polymer nanocomposites for cisplatin (IV) delivery and biomedical imaging Adv Mater 2013 25 4898 905 23857588
  41. [42]Tian G Zheng X Zhang X Yin W Yu J Wang D TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance Biomaterials 2015 40 107 16 25433607
  42. [43]Wang C Tao H Cheng L Liu Z Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles Biomaterials 2011 32 6145 54 21616529
  43. [44]Tian G Ren W Yan L Jian S Gu Z Zhou L Red-emitting upconverting nanoparticles for photodynamic therapy in cancer cells under near-infrared excitation Small 2013 9 1929 38 8 23239556
  44. [46]Yang Y Sun Y Cao T Peng J Liu Y Wu Y Hydrothermal synthesis of NaLuF4:153Sm,Yb,Tm nanoparticles and their application in dual-modality upconversion luminescence and SPECT bioimaging Biomaterials 2013 34 774 83 23117216
  45. [47]Willmann JK van Bruggen N Dinkelborg LM Gambhir SS Molecular imaging in drug development Nat Rev Drug Discov 2008 7 591 607 18591980
  46. [48]Yigit MV Moore A Medarova Z Magnetic nanoparticles for cancer diagnosis and therapy Pharm Res 2012 29 1180 8 22274558 PMC3734862
  47. [49]Raymond KN Pierre VC Next generation, high relaxivity gadolinium MR1 agents Bioconjug Chem 2005 16 3 8 15656568
  48. [50]Grange C Geninatti-Crich S Esposito G Alberti D Tei L Bussolati B Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma Cancer Res 2010 70 2180 90 20215497
  49. [51]Shukla S Steinmetz NF Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015 7 708 21 25683790 PMC4620044
  50. [52]Bruckman MA Hern S Jiang K Flask CA Yu X Steinmetz NF Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents J Mater Chem B Mater Biol Med 2013 1 1482 90 23589767 PMC3624747
  51. [53]Kobayashi T Cancer hyperthermia using magnetic nanoparticles Biotechnol J 2011 6 1342 7 22069094
  52. [54]Hayashi K Nakamura M Sakamoto W Yogo T Miki H Ozaki S Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment Theranostics 2013 3 366 76 23781284 PMC3677408
  53. [55]Yu MK Jeong YY Park J Park S Kim JW Min JJ Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo Angew Chem Int Ed Engl 2008 47 5362 5 18551493
  54. [57]Yang H Li Y Li TT Xu M Chen Y Wu CH Multifunctional Core/Shell Nanoparticles Cross-linked Polyetherimide-folic Acid as Efficient Notch-1 siRNA Carrier for Targeted Killing of Breast Cancer Sci Rep 2014 4 PMC4233336 25400232
  55. [58]Carlsson CA Imaging modalities in x-ray computerized tomography and in selected volume tomography Phys Med Biol 1999 44 R23 56 10211798
  56. [60]Kim D Jeong YY Jon S A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer ACS nano 2010 4 3689 96 20550178
  57. [61]Sun H Zhu X Lu PY Rosato RR Tan W Zu Y Oligonucleotide aptamers: new tools for targeted cancer therapy Mol Ther Nucleic Acids 2014 8 5 3 e182 25093706 PMC4221593
  58. [62]Jaque D Martinez Maestro L del Rosal B Haro-Gonzalez P Benayas A Plaza JL Nanoparticles for photothermal therapies Nanoscale 2014 6 9494 530 25030381
  59. [63]Zhang X Xing JZ Chen J Ko L Amanie J Gulavita S Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles Clin Invest Med 2008 31 E160 7 18544279
  60. [64]Hainfeld JF Slatkin DN Smilowitz HM The use of gold nanoparticles to enhance radiotherapy in mice Phys Med Biol 2004 Sep; 49: N309-N15 15509078
  61. [65]Huang P Bao L Zhang C Lin J Luo T Yang D Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy Biomaterials 2011 32 9796 809 21917309
  62. [66]Phelps ME PET: The merging of biology and imaging into molecular imaging J Nucl Med 2000 41 661 81 10768568
  63. [67]Xiao Y Hong H Javadi A Engle JW Xu W Yang Y Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging Biomaterials 2012 33 3071 82 22281424 PMC3313838
  64. [68]Bartlett DW Su H Hildebrandt IJ Weber WA Davis ME Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc Natl Acad Sci U S A 2007 104 15549 54 17875985 PMC1978218
  65. [69]Stride E Saffari N Microbubble ultrasound contrast agents: a review Proc Inst Mech Eng H 2003 217 429 47 14702981
  66. [70]Qin S Caskey CF Ferrara KW Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering Phys Med Biol 2009 54 R27 57 19229096 PMC2818980
  67. [73]Min HS You DG Son S Jeon S Park JH Lee S Echogenic Glycol Chitosan Nanoparticles for Ultrasound-Triggered Cancer Theranostics Theranostics 2015 5 1402 18 26681985 PMC4672021
  68. [74]Maeda H Wu J Sawa T Matsumura Y Hori K Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 2000 65 271 84 10699287
  69. [75]Min KH Min HS Lee HJ Park DJ Yhee JY Kim K pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers ACS nano 2015 9 134 45 25559896 PMC5242341
  70. [76]Choi BY Park HJ Hwang SJ Park JB Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents Int J Pharm 2002 239 81 91 12052693
  71. [77]Gerweck LE Seetharaman K Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer Cancer Res 1996 56 1194 8 8640796
  72. [78]Wikehooley JL Haveman J Reinhold HS The Relevance of Tumor Ph to the Treatment of Malignant Disease Radiother Oncol 1984 2 343 66 6097949
  73. [79]Goss SL Lemons KA Kerstetter JE Bogner RH Determination of calcium salt solubility with changes in pH and P-CO2, simulating varying gastrointestinal environments J Pharm Pharmacol 2007 59 1485 92 17976258
  74. [80]Kennedy JE High-intensity focused ultrasound in the treatment of solid tumours Nat Rev Cancer 2005 5 321 7 15776004
  75. [81]Deckers R Moonen CT Ultrasound triggered, image guided, local drug delivery J Control Release 2010 148 25 33 20709123
  76. [82]Ma M Xu H Chen H Jia X Zhang K Wang Q A drug-perfluorocarbon nanoemulsion with an ultrathin silica coating for the synergistic effect of chemotherapy and ablation by high-intensity focused ultrasound Adv Mater 2014 26 7378 85 25228225
  77. [83]Wang X Chen HR Zhang K Ma M Li FQ Zeng DP An Intelligent Nanotheranostic Agent for Targeting, Redox-Responsive Ultrasound Imaging, and Imaging GuidedHigh- Intensity Focused Ultrasound Synergistic Therapy Small 2014 10 1403 11 24288148

Cited by

Sorted by citations

Authors
Jo, S. D., Ku, S. H., Won, Y.-Y., Kim, S. H., & Kwon, I. C.
Affiliations
  • Korea Institute of Science and Technology (KR)
  • Purdue University West Lafayette (US)
  • Korea University (KR)
Corresponding author
  • Kim, Sun Hwa
  • Kwon, Ick Chan
ORCID
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2016
Volume
6
Issue
9
Pages
1362-1377
ISSN
1838-7640 (ISSN-L)
DOI
10.7150/thno.15335
PMC
PMC4924505
OpenAlex
W2423276331
Cited by
218
References
84
Citations by year
2026: 8 · 2025: 15 · 2024: 18 · 2023: 21 · 2022: 19 · 2021: 25 · 2020: 21 · 2019: 26 · 2018: 35 · 2017: 25 · 2016: 5
FWCI
2.17
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Theranostics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation
  • Korea Institute of Science and Technology
  • National Research Foundation of Korea (2012K1A1A2A01056095)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
Keywords
nanotheranostics, theranostic nanomaterials, multifunctional nanoparticles, cancer therapy, personalized medicine, drug delivery, drug release, tissue distribution, real-time imaging
MeSH terms
Theranostic Nanomedicine, Animals, Humans, Neoplasms, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review